Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429837 | 0.81 | SLC6A3 (0.63) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL777788 | 0.80 | LMNA (0.44) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19939782 | 0.80 | CHRNA7 (0.41) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12128404 | 0.78 | KMT2A (0.44) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12381822 | 0.76 | LMNA (0.46) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19485917 | 0.76 | DPP4 (0.44) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10967759 | 0.76 | LMNA (0.41) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14288501 | 0.76 | SLC6A3 (0.57) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7963041 | 0.75 | SLC6A3 (0.56) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6827648 | 0.75 | SLC6A3 (0.61) | SLC6A3CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964611-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138518-A2 | POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-12 | — | — | WO | disclosed |
| US-7915449-B2 | Contacting the corresponding sulfur compound with complex, bas and oxidizer; oxidation; isolation | CEPHALON FRANCE (FR) | 2011-03-29 | — | — | US | disclosed |
| US-7812193-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20080214868-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION | CEPHALON FRANCE (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080171896-A1 | Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation | CEPHALON FRANCE (FR) | 2008-07-17 | — | — | US | disclosed |
| US-7368591-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2008-05-06 | — | — | US | disclosed |
| US-7317126-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2008-01-08 | — | — | US | disclosed |
| WO-2007007054-A1 | PHTHALAMIDES, SUCCINIMIDES AND RELATED COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171896-A1 | Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation | MAOA, CYP2F1, MAOB | SLC6A3 561/4885CYP1A2 13/4885CYP3A4 25/4885 |
| US-20080214868-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION | CYP2F1, MAOA, MAOB | SLC6A3 594/4885CYP1A2 11/4885CYP3A4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.